Education
About Us
Working with TipRanks
Follow Us
Median Technologies (FR:ALMDT)
:ALMDT
Top Page
Median Technologies
(ALMDT)
Select Model
Select Model
Rating:47Neutral
Price Target:
€4.50
▼(-1.53% Downside)
The score is primarily held down by weak financial performance (ongoing losses, negative equity, and negative free cash flow). Technicals are supportive due to a clear uptrend, but overbought signals reduce confidence. Valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
AI Integration in Healthcare
Median Technologies' integration of AI in medical imaging provides a competitive edge in healthcare, improving diagnostic accuracy and patient outcomes, which is crucial for long-term growth.
Partnerships with Pharma and Research
Strategic partnerships enhance revenue opportunities and foster innovation, supporting sustainable growth and industry positioning.
Revenue Growth
Consistent revenue growth indicates expanding market reach and product adoption, which is vital for long-term business sustainability.
Negative Factors
Negative Free Cash Flow
Negative free cash flow limits financial flexibility and ability to invest in growth opportunities, posing a risk to long-term stability.
Negative Equity
Negative equity indicates financial instability, which can hinder the company's ability to secure financing and invest in future growth.
Persistent Losses
Ongoing losses and negative margins reflect operational challenges, impacting profitability and long-term viability.
Median Technologies (ALMDT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€153.54M
Dividend YieldN/A
Average Volume (3M)465.96K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth6.75%
EPS Growth15.48%
CountryFR
Employees225
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.47
Shares Outstanding36,718,388
10 Day Avg. Volume398,206
30 Day Avg. Volume465,957
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)-2.06
Price to Sales (P/S)3.05
P/FCF Ratio-3.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.00Price Target Upside31.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Median Technologies Business Overview & Revenue Model
Company DescriptionMedian Technologies (ALMDT) is a leading company specializing in medical imaging and artificial intelligence solutions, primarily targeting the healthcare sector. The company focuses on enhancing the efficiency and effectiveness of cancer diagnosis and treatment through its innovative software solutions. Its core products include imaging analysis and decision support systems that leverage AI to assist healthcare professionals in improving patient outcomes.
How the Company Makes MoneyMedian Technologies generates revenue primarily through the sale of its software solutions and services to healthcare providers, including hospitals and clinics. The company's revenue model includes licensing fees for its software, subscription fees for ongoing access to its services, and consulting fees for implementation and support. Additionally, Median often engages in partnerships with pharmaceutical companies and research institutions, which can lead to collaborative projects that provide further revenue opportunities. The company's focus on continuous innovation and integration of AI technology into its products also helps in maintaining a competitive edge, thus contributing to its earnings.
Median Technologies Financial Statement Overview
Summary
Median Technologies is facing significant financial challenges, with declining revenue and profitability, negative margins, and high leverage. The balance sheet shows negative equity, and cash flow issues further exacerbate the financial instability.Income Statement
Median Technologies has faced declining revenue and profitability over recent years. Despite some growth in revenue from 2020 to 2024, the company has consistently reported negative gross and net profit margins. The EBIT and EBITDA margins are also negative, indicating operational challenges. The negative net income and declining revenue growth rate highlight ongoing financial struggles.Balance Sheet
The company's balance sheet shows significant financial distress, with a negative stockholders' equity, indicating more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, but the large amount of debt relative to assets points to high leverage. The equity ratio is negative, further underscoring financial instability.Cash Flow
Median Technologies reports negative free cash flow, with a slight improvement in operating cash flow over recent years. The operating cash flow to net income ratio is negative, reflecting unsustainable operations. Free cash flow to net income is also negative, pointing to cash flow challenges that affect financial flexibility.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.31M | 22.95M | 22.23M | 23.67M | 20.55M | 13.48M |
| Gross Profit | -17.89M | -21.07M | -2.55M | 24.42M | 20.43M | 13.34M |
| EBITDA | -18.55M | -19.28M | -19.59M | -17.48M | -17.10M | -11.31M |
| Net Income | -21.99M | -25.24M | -22.98M | -20.21M | -19.29M | -12.80M |
Balance Sheet | ||||||
| Total Assets | 19.43M | 24.37M | 35.94M | 34.75M | 49.39M | 25.28M |
| Cash, Cash Equivalents and Short-Term Investments | 4.35M | 8.29M | 19.63M | 21.67M | 39.25M | 16.40M |
| Total Debt | 39.03M | 29.44M | 23.01M | 18.15M | 16.52M | 15.66M |
| Total Liabilities | 59.90M | 58.34M | 46.23M | 42.01M | 44.45M | 36.65M |
| Stockholders Equity | -40.47M | -33.97M | -10.29M | -7.25M | 4.94M | -11.36M |
Cash Flow | ||||||
| Free Cash Flow | -14.95M | -19.03M | -21.53M | -17.18M | -10.61M | -5.82M |
| Operating Cash Flow | -13.89M | -17.95M | -20.24M | -15.79M | -10.13M | -5.46M |
| Investing Cash Flow | -799.00K | -1.17M | -1.25M | -1.39M | -672.00K | -327.00K |
| Financing Cash Flow | 3.15M | 7.67M | 19.72M | -277.00K | 33.20M | 14.56M |
Median Technologies Technical Analysis
Positive
4.57
Price Trends
3.39
Positive
3.19
Positive
2.70
Positive
Market Momentum
0.26
Positive
57.51
Neutral
26.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMDT, the sentiment is Positive. The current price of 4.57 is above the 20-day moving average (MA) of 3.95, above the 50-day MA of 3.39, and above the 200-day MA of 2.70, indicating a bullish trend. The MACD of 0.26 indicates Positive momentum. The RSI at 57.51 is Neutral, neither overbought nor oversold. The STOCH value of 26.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALMDT.
Median Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €73.14M | -4.96 | -62.69% | ― | ― | 30.04% | |
47 Neutral | €153.54M | -3.59 | ― | ― | 6.75% | 15.48% | |
45 Neutral | €35.47M | -4.77 | -2351.12% | ― | -4.70% | -64.31% | |
45 Neutral | €28.39M | -0.78 | -49.48% | ― | 5.10% | 17.34% |
* Healthcare Sector Average
FR:ALMDT
Median Technologies
4.19
-0.58
-12.08%
FR:ALTHE
Theraclion SA
0.61
0.38
165.22%
FR:ALNOV
Novacyt
0.40
-0.28
-41.40%
FR:ALDMS
Diagnostic Medical Systems
1.29
0.57
79.17%
FR:ALIKO
Ikonisys SA
1.63
0.15
9.80%
FR:AFME
Affluent Medical SA
1.86
0.46
32.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.